Nov 4, 6:31 AM ET
United Therapeutics Corporation reported third-quarter 2026 total revenues of $832.5 million, a 4% increase year-over-year, driven by higher sales of Tyvaso DPI and Orenitram. However, net income decreased to $258.6 million, down from $338.7 million in the third quarter of 2025, largely due to increased research and development expenses associated with the Thymmune acquisition.
- Total revenues for the quarter ended September 30, 2026, rose 4% to $832.5 million compared to $799.5 million for the same period in 2025.
- Net income declined 24% to $258.6 million, or $5.71 per diluted share, compared to $338.7 million, or $7.16 per diluted share, in the third quarter of 2025.
- Research and development expenses increased 119% to $279.2 million, driven by the acquisition of Thymmune Therapeutics, Inc. and ongoing organ alternative projects.
- The board approved a new share repurchase program in October 2026 authorizing up to $2.0 billion in aggregate repurchases through October 21, 2027.
Read the filing on SEC.gov ↗
Oct 22, 7:00 AM ET
United Therapeutics' Board approved a share repurchase program of up to $2.0 billion of common stock on October 21, 2026, effective for one year through October 21, 2027. The company says the authorization gives it capacity to buy back shares, though it is not obligated to use it.
- Authorization covers up to $2.0 billion of common stock, running through October 21, 2027.
- Repurchases may be made through accelerated share repurchases, open market or privately negotiated transactions, or other means, and may start or stop at any time.
- An existing accelerated share repurchase entered in September 2026 under the prior authorization has a scheduled termination in the fourth quarter of 2026 and will not reduce the new authorization.
Read the filing on SEC.gov ↗
Sep 8, 5:12 PM ET
United Therapeutics entered an accelerated share repurchase agreement with Citibank to buy back about $477.6 million of its common stock, using the remainder of its $2 billion repurchase authorization. The company will pay the amount upfront on or around September 10, 2026, and will receive an initial delivery of about 719,376 shares, with final settlement expected in the fourth quarter of 2026.
- Upfront payment of about $477.6 million to Citibank on or around September 10, 2026
- Initial delivery of about 719,376 shares, about 75% of the shares expected under the agreement at the September 8, 2026 closing price
- Final share count depends on the average daily VWAP during the term, less a discount; final settlement expected in Q4 2026
- Company previously completed ASR agreements totaling $1.5 billion in March 2026 and bought $22.4 million in open-market purchases in Q3 2026
Read the filing on SEC.gov ↗
Aug 5, 6:33 AM ET
United Therapeutics reported second quarter 2026 results for the period ended June 30, 2026. Total revenues fell 2% to $783.3 million, while net income rose 8% to $333.0 million and diluted earnings per share rose 13% to $7.27, helped by a lower income tax expense and a lower share count.
- Total revenues were $783.3 million, down from $798.6 million in the second quarter of 2025.
- Nebulized Tyvaso revenue fell 18% to $126.0 million, while Tyvaso DPI revenue rose 4% to $326.6 million.
- Net income was $333.0 million, or $7.27 per diluted share, versus $309.5 million, or $6.41 per diluted share, a year earlier.
- As of June 30, 2026, $500 million remained under the share repurchase program, which expires March 9, 2027.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.